Search Results

101 - 110 of 280 items :

  • pharmacokinetics x
  • Clinical Medicine x
Clear All
Treatment of ventilator-associated pneumonia with high-dose colistin under continuous veno-venous hemofiltration

the 1970s because of significant renal and neurological toxicity. [ 4 ] At present, COL is increasingly put forward as salvage or first-line treatment for severe MDR-GNB infections, particularly in the ICU. [ 5 ] COL is administered intravenously as the inactive prodrug colistimethate sodium (CMS) that is hydrolyzed to COL. From a pharmacodynamic/pharmacokinetic (PK/PD) viewpoint, COL possesses rapid concentration-dependent bacterial killing against susceptible strains, but the ratio of the area under the concentration time curve of the unbound fraction to the

Open access
Quercetin, Menadione, Doxorubicin combination as a potential alternative to Doxorubicin monotherapy of acute lymphoblastic leukemia

flavonoid quercetin: pharmacokinetics and evidence for in vitro tyrosine kinase inhibition.Clin Cancer Res 1996;2:659-68 [19] Am J Clin Nutr Oct 1, 2001, vol 74, no 4 418-425 [20] Rice s.a., 2003; Loke s.a., 2008; Kanadaswami s.a., 2005

Open access
Experimental Study of the New Non-Opioid Analgesic Pyrodazol and Ketorolac in the Rats

Pharmacology of (R)- and (S)- Ketorolac. J Clin Pharmacol. 1998; 38: 25-35. 8. King TE, Joynes RL, Grau JW Tail-flick test: II. The role of supraspinal systems and avoidance learning. Behav Neurosci . 1997;111:754-767. 9. Komlos E, Porsresr J, Knole J.Morfin - prostigmin synergismus. Az. Acta. Phisiologica. Acad. Scient. Hungaricae.-1950;1: 77-83. 10. Lugo RA, Kern SE. Clinical pharmacokinetics of morphine. J. Pain Palliat Care Pharmacother. 2002; 16(4): 5-18. 11. Mathias SD, Kuppermann M, Liberman RF, Lipschutz

Open access
Parasitaemia Changes in the Course of Treatment of Severe Malaria Patients with Artemether and Quinine (A Preliminary Study)

White NJ. Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet. 1985;10(3):187-215. doi:10.2165/00003088-198510030-00001 PMID:3893840 Hosein S. Infection fighters - Artemisia - experience. Treatment information Exchange. Canada Update 60. Vol 7.

Open access
The role of Pazopanib in Soft Tissue Sarcoma: A comprehensive review of the literature

) and French Sarcoma Group (FSG) study. Br J Cancer 2011; 104:1544. [31] Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005; 23:576. [32] Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004; 22

Open access
Atomoxetine in the Treatment of the Most Common Comorbid Disorders of Attention-Deficit/Hyperactivity Disorder, Oppositional Defiant Disorder and Anxiety Disorders

-40. 19. Spencer TJ, Kratochvil CJ, Sangal RB, et al. Effects of atomoxetine on growth in children with attentiondeficit/ hyperactivity disorder following up to five years of treatment. J Child Adolesc Psychopharmacol. 2007; 17(5): 689-700. 20. Sangal RB, Owens J, Allen AJ, et al. Effects of atomoxetine and methylphenidat on sleep in children with ADHD. Sleep. 2006; 29(12): 1573-85. 21. Witcher JW, Long A, Smith B, et al. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child

Open access
Heroin Maintenance Treatment - Are the Further Investigation Needed?

Report 2010. http:// 29. Farrell M. National Addiction Centre, Institute of Psychiatry, London SE5 8AF Wayne Hall. The Swiss heroin trials: testing alternative approaches BMJ. 1998;316(7132): 639. 30. Carnwath T, Merrill J. Dose equivalents in opioid substitution treatment. International Journal of Drug Policy. 2002;13:445-447. 31. Rook EJ, Huitema AD, van den Brink W, van Ree JM, Beijnen JH. Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites

Open access
Efficacy and Tolerability of Various Antimicrobial Regimens in the Treatment of Exacerbations of Chronic Bronchitis and Chronic Obstructive Pulmonary Disease in Outpatients

chronic obstructive pulmonary disease after treatment with antimicrobials: a results of a two-years study. IMPAC Study Group. Clin Drug Invest. 2003;23:439-450. doi:10.2165/00044011-200323070-00003 PMID:17535055 Perry CM, Brogden RN. Cefuroxime Axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1996;52(1):125-156. doi:10.2165/00003495-199652010-00009 PMID:8799689 Destache CJ, Dewan N, O'Donohue WJ, et al. Clinical and economic considerations in the

Open access
Quantitative Analysis of Adrenal Cortical Histological Alterations After Application of Medroxyprogesterone Acetate

;3(2):123-131. Blossey HC, Wander HE, Koebberling J, Nagel GA, Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate. Cancer. 1984;54:1208-1215. Van Veelen H, Willemse PH, Sleijfer DT, Van der Ploeg E, Sluiter WJ, Doorenbos H. Mechanism of adrenal suppresion by high-dose medroxy-progesterone acetate in breast cancer patients. Cancer Chemother Pharmacol. 1985;15(2):167-170. Barbieri RL, Ryan KJ. Direct effects of medroxyprogesterone acetate (MPA) and

Open access
Review of a New Multimodal Antidepressant Vortioxetine

treatment of major depressive disorder. J Pharmacol Exp. Ther. 2012; 340 (3): 666-675. 7. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jørgensen M, Püschl A, Dalgaard L. Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012; 40 (7): 1357-1365. 8. Chen G, Lee R, Højer AM, Buchbjerg JK, Serenko M, Zhao Z. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig. 2013; 33: 727-736. 9

Open access